Lung Cancer News and Research

Latest Lung Cancer News and Research

Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera

Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).

27 Aug 2010

Spectral Molecular Imaging completes development of SkinSpect for melanoma detection

Cascade Technologies, Inc. announced today that its wholly owned subsidiary Spectral Molecular Imaging, Inc. (SMI) will complete development of its new product SkinSpect, aimed at early detection of melanoma by hyperspectral imaging, in mid-September 2010, significantly ahead of schedule.

27 Aug 2010

Biomoda's CyPath assay for lung cancer detection receives Canadian patent

Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.

26 Aug 2010

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the first patient has been treated in its clinical trial of STA-9090 in combination with docetaxel for the treatment of advanced solid tumor malignancies.

24 Aug 2010

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Pfizer Inc. announced today that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC).

24 Aug 2010

Early palliative care treatment for lung cancer can help patients live longer: Research

Introducing palliative care at an early stage of treatment for advanced lung cancer could help patients to live for longer, as well as improving their mood and quality of life.

23 Aug 2010

US oncology announces its contributions in development of 42 novel cancer therapies

US Oncology, Inc., the nation's leading integrated oncology company, announced today that in less than two decades it has played a role in the development of 42 novel cancer therapies approved by the US Food and Drug Administration.

21 Aug 2010

Palliative care prolongs metastatic lung cancer patient’s life: Study

A precedent-setting study published in the New England Journal of Medicine on Thursday, August 19 demonstrates definitively that early referrals to palliative care prolongs life for patients living with metastatic lung cancer.

21 Aug 2010

Cancer patients may live longer with palliative and hospice care services: Study

A new study released by the New England Journal of Medicine found that among patients with non-small-cell lung cancer, those who received palliative care lived, on average, almost two months longer than those who received standard care. Researchers also found that the patients receiving palliative care reported a higher quality of life through the final course of their illness.

20 Aug 2010

Even low-level exposure to cigarette smoke affects gene function in lungs

Casual smokers may think that smoking a few cigarettes a week is "no big deal." But according to new research from physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, having an infrequent smoke, or being exposed to secondhand smoke, may be doing more harm than people may think. The findings may further support public smoking bans, say the authors.

20 Aug 2010

Palliative care recipients live longer and in less pain, study finds

The New York Times: "In a study that sheds new light on the effects of end-of-life care, doctors have found that patients with terminal lung cancer who began receiving palliative care immediately upon diagnosis not only were happier, more mobile and in less pain as the end neared — but they also lived nearly three months longer.

20 Aug 2010

First Edition: August 19, 2010

In the news today, modest premium increases are ahead for Medicare drug plans while a survey finds that big employers expect health cost hikes in 2011.

20 Aug 2010

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

ImmunoGen, Inc., a biotechnology company that develops antibody-based targeted anticancer products, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lorvotuzumab mertansine (formerly IMGN901) product candidate when used for the treatment of small-cell lung cancer (SCLC).

19 Aug 2010

Toshiba America Medical Systems/RSNA issues grant to three researchers

The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation awarded 2010 Toshiba America Medical Systems/RSNA grants to Kenneth S. Lee, M.D., Nitin Ohri, M.D., and Ben Paxton, M.D. The grants are made possible by Toshiba's support of the RSNA R&E Foundation.

18 Aug 2010

Varian to showcase new Gated RapidArc technology at 2010 CHINA-HOSPEQ exhibition

Varian Medical Systems, Inc. will showcase the company's new Gated RapidArc technology on its Trilogy® machine with advanced motion management capabilities at the 2010 CHINA-HOSPEQ exhibition being held in Beijing August 19-21 by China's Ministry of Health. Varian, the world's leading manufacturer of medical technology for treating cancer and a premier supplier of X-ray imaging technology, will also exhibit its software for planning and for managing radiation therapy treatments.

18 Aug 2010

Study shows increase in IL-6 secretion can reduce Tarceva sensitivity to treat lung tumor cells

One of the most tantalizing developments in anti-cancer therapy over recent years has been the advent of targeted treatments, which have proven highly effective in holding aggressive cancers at bay in certain patients, although typically only for a limited period of time.

18 Aug 2010

Researcher identifies immune system's ability to protect body against lung cancer

A Michigan State University researcher is analyzing the immune system's own ability to protect the body against lung cancer.The results of the work by Alison Bauer, an assistant professor of pathobiology and diagnostic investigation in the College of Veterinary Medicine, are expected to provide new approaches to prevent, identify and treat lung cancer.

18 Aug 2010

Adult stem cells associated with poor prognosis of cancer: Research

Adult stem cells that are vital for airway repair in the lung but that persist in areas where pre-cancerous lesions are found are associated with a poor prognosis in patients who develop cancer, even those with early stage disease, researchers at UCLA's Jonsson Comprehensive Cancer Center have found.These adult stem cells are found in repairing areas after injury and also are found in pre-cancerous areas, suggesting that these cells may mutate and become cancer causing stem cells, making them a potential cell-of-origin for lung cancer and a possible target for prevention strategies and new targeted therapies.

18 Aug 2010

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.

18 Aug 2010

NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention

Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, today announced that it has been awarded a grant for $3 million from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health. The grant is aimed at advancing the development of an enhanced therapeutic nicotine vaccine for the treatment of smoking cessation and relapse prevention.

16 Aug 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera

Spectral Molecular Imaging completes development of SkinSpect for melanoma detection

Biomoda's CyPath assay for lung cancer detection receives Canadian patent

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Early palliative care treatment for lung cancer can help patients live longer: Research

US oncology announces its contributions in development of 42 novel cancer therapies

Palliative care prolongs metastatic lung cancer patient’s life: Study

Cancer patients may live longer with palliative and hospice care services: Study

Even low-level exposure to cigarette smoke affects gene function in lungs

Palliative care recipients live longer and in less pain, study finds

First Edition: August 19, 2010

FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer

Toshiba America Medical Systems/RSNA issues grant to three researchers

Varian to showcase new Gated RapidArc technology at 2010 CHINA-HOSPEQ exhibition

Study shows increase in IL-6 secretion can reduce Tarceva sensitivity to treat lung tumor cells

Researcher identifies immune system's ability to protect body against lung cancer

Adult stem cells associated with poor prognosis of cancer: Research

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

NIDA grants Selecta Biosciences $3M to develop nicotine vaccine for smoking cessation and relapse prevention

The ultimate guide to lung research tools and protocols eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in